Open Accessibility Menu
Hide

Monoclonal Antibodies for COVID-19

Available at Baxter Regional COVID-19 Infusion Center

Baxter Regional provides monoclonal antibodies for treatment of COVID-19 for patients who meet certain criteria. For more information, contact your Primary Care Provider or call the Baxter Regional COVID-19 Infusion Center at (870) 508-3010.

In November, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization to allow the use of monoclonal antibodies for the treatment of mild to moderate symptoms of COVID-19 in adults and pediatric patients.

Monoclonal antibodies are laboratory-made proteins that mimic your immune system’s ability to fight off harmful viruses. Casirivimab and Imdevimab are monoclonal antibodies that are specifically designed to protect against the spike protein of COVID-19. These proteins are designed to stop the virus from entering the human cells.

In July, 2021, the FDA expanded the monoclonal antibodies EUA to include post-exposure prophylaxis for COVID-19 in those 12 years of age and older who are at high risk for progression to severe COVID-19, including hospitalization or death. Please reference the Fact Sheet for Health Care Providers Emergency Use Authorization of REGEN-COV™ (casirivimab and imdevimab) for more detail.

Note: Post-exposure prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19, and REGEN-COV is not authorized for pre-exposure prophylaxis.

Who Can Get This Treatment?

Monoclonal antibodies are for non-hospitalized COVID-19 patients with mild to moderate symptoms with less than 10 days since symptom onset in one of the following high-risk categories.

  • Age 65 and older, weighing 80 lbs or more
  • Those told by their doctor that you are at high risk for a serious case of COVID-19
  • Pregnancy
  • Age 12 or older, weighing at least 80 lbs and have any of the following conditions:
    • Diabetes
    • Any immunosuppressive, heart, lung or chronic kidney disease
    • BMI of 25 or greater
    • Neurodevelopmental disorders
    • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19)

The treatment is NOT approved for use in patients who are hospitalized due to COVID-19 or require oxygen therapy. Benefits of treatment have not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies may be associated with worse clinical outcomes when given to patients with COVID-19 requiring oxygen ventilation. Individual administration sites may have additional criteria for use of these monoclonal antibody therapies in patients.

For more information about monoclonal antibodies for treatment of COVID-19, contact your Primary Care Provider or the Baxter Regional COVID-19 Infusion Center at (870) 508-3010.

Click here for guidance about monoclonal antibodies from the Arkansas Department of Health.

Related Blogs